Anti-Tumor Derivatives for Differentiation Therapy


James Phillips, PhD
Yogen Saunthararajah, MD
Kwok Peng Ng, PhD
Babal Kant Jha, PhD
Anand Tiwari, PhD


What is it? What does it do?

  • The pharmaceutical compositions includes one or more imidazopyridine derivatives together with one or more of a variety of physiological acceptable carriers for delivery to a patient.
  • These imidazopyridine derivatives of the invention can be used for both prophylactic and therapeutic treatment.

Why is it better?

  • Conventional anti-metabolite and kinase inhibitor oncotherapy is not only toxic but rarely cures disease.  Unlike current anti-metabolite or kinase-inhibitor drugs the developed compounds allow cell division, in the process restoring differentiation mediated cell cycle exit to malignant stem cells, but maintaining self-renewal of normal stem cells.
  • Compounds derived from the invented method have promise for increased efficacy and less toxicity as a novel approach to treating cancers including AML, bladder, breast, colon, liver, lung, myeloma and prostate.

What is its current status?

Cell line and animal model validation achieved.





Other Technologies by Inventor

Other Technologies by Innovation Manager

Get in Touch With Us